A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of empagliflozin in healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

NCT01947855

Diabetes Mellitus, Type 2

COMPLETED PHASE3

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

NCT04018365

Insulin Resistance - Type A Insulin Resistance - Type B Lipoatrophic Diabetes Mellitus +1 more

UNKNOWN PHASE3

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

NCT01193218

Diabetes Mellitus, Type 2

COMPLETED PHASE2

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

NCT00885118

Diabetes Mellitus, Type 2

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 10773 Arm

BI 10773 high dose once daily

Group Type EXPERIMENTAL

BI 10773

Intervention Type DRUG

BI 10773 tablets once daily high dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 10773

BI 10773 tablets once daily high dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients diagnosed with IGT according to the current ADA guidelines as a two-hour glucose levels of 140 to 199 mg/dl (7.8 mmol/l to 11.1 mmol/l) on the 75-g oral glucose tolerance test (OGTT), with an OGTT performed at the time of the screening visit (Visit 1), or

¿ Male and female patients diagnosed with type 2 diabetes mellitus (T2DM) prior to informed consent, on diet and exercise regimen who are drug-naïve, defined as absence of any oral antihyperglycemic therapy for 12 weeks prior starting with open-label active treatment, or
2. Male and female patients diagnosed with type 2 diabetes mellitus prior to informed consent, who are pre-treated with metformin background therapy, on a stable dose of metformin of at least 1500 mg per day, unchanged for at least 12 weeks prior starting with open-label active treatment
3. HbA1c at Visit 1 (screening)

1. for patients diagnosed of IGT and for healthy subjects: HbA1c \< 6.5%
2. for patients diagnosed of T2DM: HbA1c =6.5% and =10.5%
4. Age = 18 at Visit 1
5. BMI = 20 and = 40 Kg/m2 at Visit 1
6. For patients with antihypertensive treatment, this must be stable (with no change in dosage) within 4 weeks prior starting with open-label active treatment
7. Signed and dated written informed consent by date of Visit 1 in accordance with GCP and local legislation

8. Males or females matching the below mentioned criteria and otherwise healthy according to the investigator¿s assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (BP, PR) and clinical laboratory tests .
9. HbA1c at Visit 1 (screening): HbA1c \< 6.5%
10. Confirmed normal glucose tolerance (NGT) by OGTT
11. Age = 45 and = 55 at Visit 1.
12. BMI = 30 and = 40 Kg/m2 (Body Mass Index) at Visit 1.
13. Signed and dated written informed consent by date of Visit 1 in accordance with GCP and local legislation.

Exclusion Criteria

1. Acute coronary syndrome (non-STEMI \[ST elevation myocardial infarction\], STEMI, unstable AP \[angina pectoris\]), stroke or Transient Ischemic Attack (TIA) within 6 months prior to informed consent.
2. Uncontrolled hyperglycaemia with a glucose level \> 240 mg/dl (\> 13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).
3. Any other antidiabetic drug within 12 weeks prior to starting the open-label active treatment (Visit 4) except those defined as background via inclusion criterion 1c.
4. Indication of liver disease, defined by serum levels of either Alanine Aminotransferase (ALT \[SGPT\]), Aspartate Aminotransferase (AST \[SGOT\]), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening and/or run-in phase.
5. Impaired renal function, defined as estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min (moderate and severe renal impairment) as determined during screening and/or run-in phase.
6. Medical history of insufficient bladder emptying (i.e. neurogenic bladder disorders).
7. Patients with an Haemoglobin (Hb) \< 11.5 g/dl (for males) and Hb \< 10.5 g/dl (for females) at Visit 1.
8. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption within the last 5 years.
9. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
11. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.
12. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except T2DM. However, the use of inhaled steroids (e.g., for asthma, Chronic Obstructive Pulmonary Disease \[COPD\]) is not an exclusion as these do not cause systemic steroid action.
13. Alcohol or drug abuse (according to investigators judgment) within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake.
14. Intake of an investigational drug in another trial Participation in another trial within 30 days prior to intake of study medication in this trial.
15. Pre-menopausal women (last menstruation \< = 1 year prior to informed consent) who:

Are nursing or pregnant or Are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
16. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes